Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K's Heptares Signs Up AstraZeneca In Latest GPCR-Focused Discovery Pact

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca becomes the third Big Pharma in six weeks to sign up for U.K-based Heptares' GPCR stabilizing technology.
Advertisement

Related Content

Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University
Shire Exercises Option On Heptares' Preclinical Candidate In $190 Million Deal
AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures
AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures
Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy
Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
Takeda To Hunt For New CNS Therapeutics With Heptares' Technology

Topics

Advertisement
UsernamePublicRestriction

Register

PS072314

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel